- Home
- FGNX vs FATE Comparison
FGNX vs FATE Comparison
Compare FGNX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGNX | FATE |
|---|---|---|
| Founded | 1932 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.4M | 139.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | FGNX | FATE |
|---|---|---|
| Price | $1.72 | $1.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $8.50 | $3.92 |
| AVG Volume (30 Days) | 463.6K | ★ 1.7M |
| Earning Date | 03-26-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,450,000.00 | $7,137,000.00 |
| Revenue This Year | $95.83 | N/A |
| Revenue Next Year | $42.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 144.71 | N/A |
| 52 Week Low | $1.59 | $0.66 |
| 52 Week High | $41.25 | $1.94 |
Technical Indicators
Market Signals| Indicator | FGNX | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 25.03 | 54.36 |
| Support Level | $1.59 | $1.07 |
| Resistance Level | $2.98 | $1.26 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 9.22 | 55.36 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc is a capital markets platform focused on long-term Ethereum (ETH) accumulation and on-chain yield generation. The company provides institutional investors with secure, regulated access to ETH as a productive reserve asset, generating native staking yield while underpinning stablecoins, tokenized assets, and AI-driven applications.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.